Images List Premium Download Classic

Liver Disease

Liver Disease-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
NEW Tgr5 modulators and methods of use thereof
January 18, 2018 - N°20180016295

Or a salt, solvate, hydrate, or prodrug thereof. The compounds of formula a are tgr5 modulators useful for the treatment of various diseases, including metabolic disease, inflammatory disease, liver disease, autoimmune disease, cardiac disease, kidney disease, cancer, and gastrointestinal disease.
NEW Drug for inhibiting adipose cell differentiation and insulin resistance
Beijing Protgen Ltd.
January 18, 2018 - N°20180015148

The present invention provides use of endostatin or a functional variant thereof in the preparation of a medicament for treating dietary obesity, non-alcoholic fatty liver disease, insulin resistance or glucose intolerance. In the embodiments of the present invention, the functional variant may be yh-16, mes, myh-16, m003, m007, mz101, or the like.
Pharmaceutical compositions for combination therapy
Intercept Pharmaceuticals, Inc.
January 11, 2018 - N°20180008616

The present invention relates to a pharmaceutical composition comprising a combination of an fxr agonist and at least one lipid lowering agent (e. G., ppar-alpha agonist, ppar-delta agonist, ppar-alpha and delta dual agonist, and/or statin). Also disclosed is use of the combination for the treatment or prevention of a fxr mediated disease or condition, such as primary biliary cirrhosis (...
Liver Disease Patent Pack
Download 100+ patent application PDFs
Liver Disease Patent Applications
Download 100+ Liver Disease-related PDFs
For professional research & prior art discovery
inventor
  • 100+ full patent PDF documents of Liver Disease-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Treatment for non-alcoholic fatty liver diseases
Dsm Ip Assets B.v.
January 04, 2018 - N°20180000775

The present invention relates to the use of mixtures of vitamin e and polyunsaturated fatty acids (pufas) as agents for the prevention, control and/or treatment of conditions associated with excessive fat accumulation in the liver which is not caused by alcohol abuse. This includes prevention, control and/or treatment of non-alcoholic steatosis in the liver—known as non-alcoholic ...
Biomarkers for fatty liver disease and methods using the same
Metabolon, Inc.
December 28, 2017 - N°20170370954

Biomarkers of nash, nafld, and fibrosis and methods for diagnosis (or aiding in the diagnosis) of nafld, nash and/or fibrosis are described herein. Additionally, methods of distinguishing between nafld and nash, methods of classifying the stage of fibrosis, methods of determining the severity of liver disease, methods of determining the severity of liver disease or fibrosis, and methods of ...
Herbal drug composition containing probiotic and optionally prebiotic and/or active pharmaceutical ingredient
Vitaliva, Llc
December 28, 2017 - N°20170368135

The embodiments herein relate to the combination of herbal and probiotic (optionally with prebiotic) treatment for chronic liver diseases to be novel and more effective. Embodiments herein relate to a composition comprising a probiotic and a medicinal herb (and optionally a prebiotic), wherein the composition is effective in treating a liver disease such as inflammation of liver in a novel ...
Liver Disease Patent Pack
Download 100+ patent application PDFs
Liver Disease Patent Applications
Download 100+ Liver Disease-related PDFs
For professional research & prior art discovery
inventor
  • 100+ full patent PDF documents of Liver Disease-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
Lumena Pharmaceuticals Llc
December 28, 2017 - N°20170368085

Provided herein are methods of treating or ameliorating a pediatric cholestatic liver disease by non-systemically administering to an individual in need thereof a therapeutically effective amount of a pediatric formulation comprising an apical sodium-dependent bile acid transporter inhibitor (asbti) or a pharmaceutically acceptable salt thereof. Also provided are methods for treating or ameliorating a pediatric liver disease, decreasing the levels ...
Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
Genfit
December 28, 2017 - N°20170368007

The invention provides 1,3-diphenylprop-2-en-1-one derivatives and pharmaceutical compositions comprising the same for treating liver disorders, in particular those requiring the reduction of plasma level of biochemical markers such as aminotransferases. The 1,3-diphenylprop-2-en-1-one derivatives of general formula (i) have hepatoprotective properties and can be used in methods for treating liver disorders involving the pathological disruption, inflammation, degeneration, ...
Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid ...
Ardelyx, Inc
December 28, 2017 - N°20170368004

The present disclosure is directed to compounds and methods for the treatment of disorders associated with fluid retention or salt overload, such as heart failure (in particular, congestive heart failure), chronic kidney disease, end-stage renal disease, liver disease, and peroxisome proliferator-activated receptor (ppar) gamma agonist-induced fluid retention. The present disclosure is also directed to compounds and methods for the treatment ...
Co-agonists of the glucagon and glp-1 receptors
Merck Sharp & Dohme Corp.
December 21, 2017 - N°20170360893

Described are peptide analogs of glucagon, which have been modified to be resistant to cleavage and inactivation by dipeptidyl peptidase iv (dpp-iv) and to increase in vivo half-life of the peptide analog while enabling the peptide analog to have relatively balanced agonist activity at the glucagon-like peptide 1 (glp-1) receptor and the glucagon (gcg) receptor, and the use of such glp-1 ...
Compositions and methods for treating intestinal hyperpermeability
December 21, 2017 - N°20170360736

The present invention provides methods, compositions, and kits for treating intestinal hyperpermeability in a subject in need thereof, including conditions such as hyperglycemia and underlying diseases such as diabetes, autism, fibromyalgia, inflammatory bowel disease (ibd), graft versus host disease (gvhd), hiv/aids, multiple organ dysfunction syndrome, irritable bowel syndrome (ibs), celiac disease, eczema, psoriasis, acute pancreatitis, parkinson's disease, depression, chronic ...
Treatment of diseases associated with hepatic stellate cell activation using ammonia-lowering therapies
Ucl Business Plc
December 14, 2017 - N°20170354627

Disclosed herein are methods of preventing, treating, and delaying the onset or progression of diseases associated with hepatic stellate cells (hscs), such as non-alcoholic fatty liver disease (nafld), fibrosis, and liver cancer, using ammonia-lowering therapies.
Sirna compositions that specifically downregulate expression of a variant of the pnpla3 gene and methods ...
Purdue Research Foundation
December 07, 2017 - N°20170349903

The invention provides sirna compositions that specifically downregulates expression of a variant of the pnpla3 gene and methods of use thereof for treating a chronic liver disease or alcoholic liver disease (ald).
Liver Disease Patent Pack
Download 100+ patent application PDFs
Liver Disease Patent Applications
Download 100+ Liver Disease-related PDFs
For professional research & prior art discovery
inventor
  • 100+ full patent PDF documents of Liver Disease-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Treating liver diseases with interleukin 24
National Cheng Kung University
December 07, 2017 - N°20170348389

Methods of treating liver diseases such as liver fibrosis using an interleukin 24 (il-24) protein.
Method of treating liver fibrosis
Chemocentryx, Inc.
December 07, 2017 - N°20170348293

A method of treating liver fibrosis with ccr2 antagonists is provided. The liver fibrosis may be associated with non-alcoholic steatohepatitis (nash), non-alcoholic fatty liver disease (nafld), emerging cirrhosis, non-cirrhotic hepatic fibrosis, type 2 diabetes mellitus (t2dm) or metabolic syndrome (ms).
Methods of liver disease treatment
December 07, 2017 - N°20170347696

Methods for treatment of chronic liver disease and reversing liver fibrosis are provided. These treatments may be achieved using a medical food composition. The medical food is configured specifically for those having chronic liver disease to provide for specific nutritional requirements caused by the chronic liver disease. Testing of the treated patient allows for tracking of progress and to determine ...
Method for measuring bile salt export transport and/or formation activity
Biotranex, Llc
November 30, 2017 - N°20170343535

A method is provided to measure modulation of bile salt export transport and/or formation activity in hepatocyte or stable cell line preparations by test agents including but not limited to drugs, drug candidates, biologicals, food components, herb or plant components, proteins, peptides, dna, rna. Furthermore, the method is to determine modulation of bile salt export transport and/or formation ...
Adenovirus ad36 e4orf1 protein for prevention and treatment of non-alcoholic fatty liver disease
Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College
November 30, 2017 - N°20170340699

This invention generally relates to methods for treating or preventing the symptoms of non-alcoholic fatty liver disease, methods for reducing excessive fat from the liver, methods of improving glycemic control, and methods for treating or preventing liver dysfunction, that comprise administering a therapeutically effective amount of adenovirus 36 e4orf1 protein or functional variant thereof.
Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
Alnylam Pharmaceuticals, Inc.
November 30, 2017 - N°20170340661

The present invention relates to rnai agents, e. G., double stranded rnai agents, targeting the patatin-like phospholipase domain containing 3 (pnpla3) gene, and methods of using such rnai agents to inhibit expression of a pnpla3 gene and methods of treating subjects having nonalcoholic fatty liver disease (nafld) and/or a pnpla3-associated disorder.
Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid ...
Ardelyx, Inc.
November 30, 2017 - N°20170340623

The present disclosure is directed to compounds and methods for the treatment of disorders associated with fluid retention or salt overload, such as heart failure (in particular, congestive heart failure), chronic kidney disease, end-stage renal disease, liver disease, and peroxisome proliferator-activated receptor (ppar) gamma agonist-induced fluid retention. The present disclosure is also directed to compounds and methods for the treatment ...
Piperidinylpyrazolopyrimidinones and their use
Bayer Pharma Aktiengesellschaft
November 23, 2017 - N°20170334917

The present application relates to novel substituted piperidinylpyrazolopyrimidinones, to processes for their preparation, the compounds for use alone or in combinations in a method for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of acute and recurrent bleeding in patients with or without underlying hereditary or acquired hemostatic disorders, wherein the bleeding is ...
Loading